[The impact of fusafungine on the prescription of antibiotics in the treatment of rhinopharyngitis].
OBJECTIVE
The analysis in France, during the period 01/12/99 to 30/11/2000, of the prescription of systemic antibiotics in patients with rhinopharyngitis and of the variables statistically related to such prescriptions and the potential role of fusafungine in the form of a rhinopharyngeal spray.


METHODS
A retrospective study, based on a panel of 1,010 general practitioners, in a cohort of 30,568 patients presenting with rhinopharyngitis. The fusafungine group consisted of 16,076 patients who had rhinopharyngitis and in whom fusafungine was prescribed. The control group consisted of 14,492 patients with rhinopharyngitis without prescription of fusafungine. The overall rate of antibiotic prescription was documented. A stepwise statistical analysis was conducted to specify the variables statistically associated with the prescription of a systemic antibiotic. The rate of prescription of a systemic antibiotic and the cost of the treatment were also compared within both groups.


RESULTS
The overall rate of systemic antibiotic prescription was 52.9%, falling from 60.4% in the group without fusafungine down to 46.2% in the group with fusafungine (p<0.01) whichever the systemic antibiotic prescribed. The stepwise analysis documented various variables that appear to be related to the systemic antibiotic prescription. A saving of 0.7 euros per prescription was noted in the fusafungine group.


CONCLUSIONS
Although various variables appear to influence systemic antibiotic prescription in patients with rhinopharyngitis, our study shows that prescription of fusafungine in spray from led to statistically significant reduction in systemic antibiotic prescription.
Laccourreye
Ollivier
O
Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Hôpital Européen Georges-Pompidou, Paris.
Cauchois
Régis
R
Landais
Paul
P
German-Fattal
Michèle
M
D000293:Adolescent; D000328:Adult; D000336:Aerosols / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003365:Costs and Cost Analysis; D003627:Data Interpretation, Statistical; D047630:Depsipeptides; D011307:Drug Prescriptions; D005260:Female; D005670:Fusarium; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009304:Nasopharyngitis / Q000188:drug therapy* / Q000191:economics; D012189:Retrospective Studies
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin
Impact de la fusafungine sur la prescription d'antibiotiques dans le traitement de la rhinopharyngite en France.